HbA1c reduction with tirzepatide in people with type 2 diabetes: a mediation analysis using body weight loss as a factor

被引：0
|
作者：
Vilsboll, T. [1 ]
Nicolay, C. [2 ]
Malecki, M. [3 ]
Thieu, V. Thuyanh [2 ]
Chivukula, K. [2 ]
Kiljanski, J. [2 ]
机构：
[1] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Ctr Clin Metab Res, Herlev, Denmark
[2] Eli Lilly & Co, Indianapolis, IN USA
[3] Jagiellonian Univ, Dept Metab Dis, Med Coll, Krakow, Poland
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
643
引用
收藏
页码：S324 / S325
页数：2
相关论文
共 50 条
  • [31] Diabetes and Weight Loss: The Effect of a structured Obesity Therapy Program on the Body Composition and HbA1c
    Kruschitz, Renate
    Wallner-Liebmann, Sandra Johanna
    Lothaller, Harald
    Luger, Maria
    Scheibner, Peter
    Ludvik, Bernhard
    WIENER KLINISCHE WOCHENSCHRIFT, 2013, 125 : S26 - S26
  • [32] Systolic blood pressure reduction with tirzepatide across SURPASS programme: a mediation analysis using weight loss as a factor
    Mosenzon, O.
    Lingvay, I.
    Brown, K.
    Cui, X.
    Lando, L. Fernandez
    Patel, H.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S284 - S285
  • [33] HbA1c variability associated with dementia risk in people with type 2 diabetes
    Moran, Chris
    Whitmer, Rachel A.
    Dove, Zoe
    Lacy, Mary E.
    Soh, Yenee
    Tsai, Ai-Lin
    Quesenberry, Charles P.
    Karter, Andrew J.
    Adams, Alyce S.
    Gilsanz, Paola
    ALZHEIMERS & DEMENTIA, 2024, 20 (08) : 5561 - 5569
  • [34] HbA1c variability, in addition to mean HbA1c, predicts incident hip fractures in Chinese people with type 2 diabetes
    Lui, D. T. W.
    Lee, C. H.
    Chan, Y. H.
    Chow, W. S.
    Fong, C. H. Y.
    Siu, D. C. W.
    Tse, H. F.
    Woo, Y. C.
    Lam, K. S. L.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (10) : 1955 - 1964
  • [35] HbA1c variability, in addition to mean HbA1c, predicts incident hip fractures in Chinese people with type 2 diabetes
    D.T.W. Lui
    C.H. Lee
    Y.H. Chan
    W.S. Chow
    C.H.Y. Fong
    D.C.W. Siu
    H.F. Tse
    Y.C. Woo
    K.S.L. Lam
    Osteoporosis International, 2020, 31 : 1955 - 1964
  • [36] Glycaemic control with tirzepatide in people with type 2 diabetes by baseline HbA1c ≤ 69.4 mmol/mol or >69.4 mmol/mol
    De Block, C.
    Aleppo, G.
    Levine, J. A.
    Valderas, E. G.
    Benneyworth, B. D.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S315 - S315
  • [37] HbA1c levels and hospital admission in people with type 1 diabetes
    Govan, L.
    DIABETOLOGIA, 2010, 53 : S97 - S97
  • [38] Reduction of HbA1c and diabetes-related distress after intervention in a diabetes day care clinic in people with type 2 diabetes but not with type 1 diabetes
    Kuniss, Nadine
    Mueller, Ulrich Alfons
    Kloos, Christof
    Wolf, Gunter
    Kramer, Guido
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2018, 126 (04) : 242 - 248
  • [39] Canagliflozin reduces both HbA1c and body weight in patients with type 2 diabetes mellitus on background metformin
    Langslet, G.
    Davidson, J. A.
    Valentine, V.
    Vijapurkar, U.
    Canovatchel, W.
    Meininger, G.
    DIABETOLOGIA, 2014, 57 : S348 - S348
  • [40] Canagliflozin is superior to sitagliptin in reducing both HbA1c and body weight in patients with type 2 diabetes mellitus
    Schernthaner, G.
    Hieronymus, L.
    Jodon, H.
    Vijapurkar, U.
    Meininger, G.
    Canovatchel, W.
    DIABETOLOGIA, 2015, 58 : S351 - S352
12345